Boundless Bio, Inc. Common Stock (BOLD NASDAQ) stock market data APIs

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA. The company's lead product candidate is ecDTx, BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. The company offers ECHO, an ecDNA diagnostic test to detect ecDNA in patient tumor specimen; and Spyglass platform, a platform to identify druggable targets in oncogene amplified cancers. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.